|
業務類別
|
Biotechnology |
|
業務概覽
|
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for thetreatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies bytargeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties. |
| 公司地址
| 221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453 |
| 電話號碼
| +1 650 394-5230 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.apogeetherapeutics.com |
| 員工數量
| 261 |
| Dr. Carl Dambkowski, M.D. |
Chief Medical Officer |
美元 540.00K |
24/04/2026 |
| Ms. Jane Pritchett Henderson |
Chief Financial Officer and Principal Accounting Officer |
美元 540.00K |
24/04/2026 |
| Dr. Michael Henderson, M.D. |
Chief Executive Officer and Director |
美元 700.00K |
24/04/2026 |
|
|
| Mr. Mark C. McKenna |
Chairman of the Board |
24/04/2026 |
| Mr. Nimish Shah |
Independent Director |
24/04/2026 |
| Dr. Michael Henderson, M.D. |
Chief Executive Officer and Director |
24/04/2026 |
| Mr. William Jones, Jr |
Independent Director |
24/04/2026 |
| Mr. Peter Harwin |
Independent Director |
24/04/2026 |
| Mr. Tomas Kiselak |
Independent Director |
24/04/2026 |
| Ms. Jennifer A. Fox |
Independent Director |
24/04/2026 |
| Dr. Lisa L. Bollinger, M.D. |
Independent Director |
24/04/2026 |
| Dr. Andrew Gottesdiener, M.D. |
Independent Director |
24/04/2026 |
|
|
|
|
